© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 24, 1857-1863,
December 18, 1996
© 1996 Oxford University Press
Phase I Study of a Recombinant Adenovirus-Mediated Gene Transfer in Lung Cancer Patients
Institut Gustave-Roussy Villejuif, France
Transgene, Strasbourg, France
Correspondence to: Thomas Tursz, M.D., Institut Gustave-Roussy, rue Camille Desmoulins, 94805 Villejuif, France.
BACKGROUND: Despite vigorous efforts at curbing tobacco consumption and aggressive combined-modality treatment programs, both the incidence of and the mortality from lung cancer have remained virtually unchanged in the last 10 years. More effective innovative therapies are clearly needed. The direct transfer into tumor cells of tumor suppressor genes or toxic gene products that specifically promote tumor cell death and spare nonmalignant cells is a potentially novel anticancer treatment approach that should be investigated. Purpose: On the basis of compelling preclinical data, we initiated a phase I study involving six patients with inoperable lung cancer and an endobronchial lesion accessible by bronchoscopy. Our purpose was to evaluate the feasibility, tolerance, and clinical, biologic, and immunologic effects of the intratumoral administration of a recombinant, replication-deficient adenovirus (rAd.RSV
-gal), using the Rous sarcoma virus promoter to drive transcription of the Escherichia coli lacZ marker gene that encodes for the bacterial enzyme -galactosidase (-gal).
METHODS: From June 1994 through April 1995, six patients (five males and one female) were enrolled in the trial. A single dose of recombinant virus suspension containing 107 or 108 plaque-forming units (PFU) was injected intratumorally into two successive cohorts of three patients. Eligible patients received concomitant chemotherapy. Patients were kept under isolation conditions from 3 days before the injection was given until virus excretion was undetectable. Biopsyspecimens of the tumor and surrounding mucosa were collected on the 8th day and at 1, 2, and 3 months after injection. They were analyzed by cell culture, polymrase chain reaction (PCR), and -gal expression for the presence of recombinant adenovirus. So that the risk of virus recombination or complementation could be minimized, wild-type adenovirus carriers among the hospital staff (identified by PCR) were excluded from contact with patients who were potentially excreting recombinant virus.
RESULTS: -gal was expressed in tumor biopsy specimens of three patients (one who received the 107 PFU dose level and two who received 108). Bronchoalveolar lavage specimens collected immediately after injection were positive for recombinant adenovirus when analyzed in culture and by PCR. All biologic fluids were negative for recombinant virus as judged by PCR after day 12, with the exception of bronchoalveolar lavage specimens (positive PCR up to 90 days in two of three patients treated with 108 PFU). The blood samples obtained from the three patients treated with 108 PFU showed positive PCR results immediately after virus injection. Patients were kept in isolation for a median of 17 days. The most common toxic effects were moderate bleeding (occurring in two patients) during bronchoscopy and fever (seen in four patients). Endoscopic and clinically objective antitumor responses were seen in four patients, including one patient who showed a complete response by pathologic evaluation. The median survival for the patients was 12.5 months (range, 3–16+ months). Throughout the study, hospital staff remained negative for recombinant adenovirus infection.
CONCLUSIONS: This ongoing phase I study has demonstrated that a recombinant adenovirus-mediated marker gene, such as rAd.RSV-gal, can be safely introduced into humans and that the gene product is expressed by lung tumor cells of the host. [J Natl cancer Inst 1996;88:1857–63]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Duces, R. Karaky, D. Martel-Renoir, L. Mir, Y. Hamma-Kourbali, I. Bieche, P. Opolon, J. Delbe, J. Courty, M. Perricaudet, et al. 16-kDa fragment of pleiotrophin acts on endothelial and breast tumor cells and inhibits tumor development Mol. Cancer Ther., September 1, 2008; 7(9): 2817 - 2827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Appaiahgari, R. M. Pandey, and S. Vrati Seroprevalence of Neutralizing Antibodies to Adenovirus Type 5 among Children in India: Implications for Recombinant Adenovirus-Based Vaccines Clin. Vaccine Immunol., August 1, 2007; 14(8): 1053 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Wilderman, J. Sun, A. S. Jassar, V. Kapoor, M. Khan, A. Vachani, E. Suzuki, P. A. Kinniry, D. H. Sterman, L. R. Kaiser, et al. Intrapulmonary IFN-{beta} Gene Therapy Using an Adenoviral Vector Is Highly Effective in a Murine Orthotopic Model of Bronchogenic Adenocarcinoma of the Lung Cancer Res., September 15, 2005; 65(18): 8379 - 8387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sangro, G. Mazzolini, J. Ruiz, M. Herraiz, J. Quiroga, I. Herrero, A. Benito, J. Larrache, J. Pueyo, J. C. Subtil, et al. Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors J. Clin. Oncol., April 15, 2004; 22(8): 1389 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Nwanegbo, E. Vardas, W. Gao, H. Whittle, H. Sun, D. Rowe, P. D. Robbins, and A. Gambotto Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States Clin. Vaccine Immunol., March 1, 2004; 11(2): 351 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Simpson, W. A. H. Wallace, M. E. Marsden, J. R. W. Govan, D. J. Porteous, C. Haslett, and J.-M. Sallenave Adenoviral Augmentation of Elafin Protects the Lung Against Acute Injury Mediated by Activated Neutrophils and Bacterial Infection J. Immunol., August 1, 2001; 167(3): 1778 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nemunaitis, F. Khuri, I. Ganly, J. Arseneau, M. Posner, E. Vokes, J. Kuhn, T. McCarty, S. Landers, A. Blackburn, et al. Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer J. Clin. Oncol., January 15, 2001; 19(2): 289 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Molinier-Frenkel, H. Gahery-Segard, M. Mehtali, C. Le Boulaire, S. Ribault, P. Boulanger, T. Tursz, J.-G. Guillet, and F. Farace Immune Response to Recombinant Adenovirus in Humans: Capsid Components from Viral Input Are Targets for Vector-Specific Cytotoxic T Lymphocytes J. Virol., August 15, 2000; 74(16): 7678 - 7682. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. S. Moreb, C. Maccow, M. Schweder, and J. Hecomovich Expression of Antisense RNA to Aldehyde Dehydrogenase Class-1 Sensitizes Tumor Cells to 4-Hydroperoxycyclophosphamide In Vitro J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 390 - 396. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. M. Albelda, R. Wiewrodt, and J. B. Zuckerman Gene Therapy for Lung Disease: Hype or Hope? Ann Intern Med, April 18, 2000; 132(8): 649 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. N. ROM, J. G. HAY, T. C. LEE, Y. JIANG, and K.-M. TCHOU-WONG Molecular and Genetic Aspects of Lung Cancer Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1355 - 1367. [Full Text]
|
|
|
|
 |
|
 P. A. Bunn Jr., A. Soriano, G. Johnson, and L. Heasley New Therapeutic Strategies for Lung Cancer : Biology and Molecular Biology Come of Age Chest, April 1, 2000; 117(4_suppl_1): 163S - 168S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Claudio, M. Caputi, and A. Giordano The RB2/p130 Gene: The Latest Weapon in the War against Lung Cancer? Clin. Cancer Res., March 1, 2000; 6(3): 754 - 764. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. O Hiltunen, M. P Turunen, M. Laitinen, and S. Yla-Herttuala Insights into the molecular pathogenesis of atherosclerosis and therapeutic strategies using gene transfer Vascular Medicine, February 1, 2000; 5(1): 41 - 48. [Abstract] [PDF]
|
|
|
|
|
|
J. P. F. Latham, P. F. Searle, V. Mautner, and N. D. James Prostate-specific Antigen Promoter/Enhancer Driven Gene Therapy for Prostate Cancer: Construction and Testing of a Tissue-specific Adenovirus Vector Cancer Res., January 1, 2000; 60(2): 334 - 341. [Abstract] [Full Text]
|
|
|
|
|
|
E. Vigne, I. Mahfouz, J.-F. Dedieu, A. Brie, M. Perricaudet, and P. Yeh RGD Inclusion in the Hexon Monomer Provides Adenovirus Type 5-Based Vectors with a Fiber Knob-Independent Pathway for Infection J. Virol., June 1, 1999; 73(6): 5156 - 5161. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. G. Swisher, J. A. Roth, J. Nemunaitis, D. D. Lawrence, B. L. Kemp, C. H. Carrasco, D. G. Connors, A. K. El-Naggar, F. Fossella, B. S. Glisson, et al. Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer J Natl Cancer Inst, May 5, 1999; 91(9): 763 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Smith and B. R Goldspiel Cancer gene therapy update Journal of Oncology Pharmacy Practice, March 1, 1999; 5(1): 7 - 21. [Abstract] [PDF]
|
|
|
|
|
|
H. Gahery-Segard, F. Farace, D. Godfrin, J. Gaston, R. Lengagne, T. Tursz, P. Boulanger, and J.-G. Guillet Immune Response to Recombinant Capsid Proteins of Adenovirus in Humans: Antifiber and Anti-Penton Base Antibodies Have a Synergistic Effect on Neutralizing Activity J. Virol., March 1, 1998; 72(3): 2388 - 2397. [Abstract] [Full Text] [PDF]
|
|